Joint Preservation Therapy Solutions in Reno, NV

CDC PLACES vs. JE: two files, not one brochure

Adult arthritis here is 23.7% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. CDC PLACES (2023, crude) estimates 9.5% of adults in Reno have diagnosed diabetes — 2.5 points below the U.S. 12% figure. Together those PLACES numbers are why a city of 250k–500k still needs separate PRP and CTP protocols. joint preservation therapy inventory is national; utilization is JE-local.

Where Reno programs actually stall

• Adult arthritis here is 23.7% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 13% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Nevada.
• HCT/P 361 products must be minimally manipulated and used homologously. Nevada medical boards and the FTC have both acted against regenerative advertising that implies stem-cell cures. Inventory choice and website copy have to match.
• Nevada is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).

Uninsured mix and Medicare CTPs in the same building

America’s Health Rankings (BRFSS 2024) only publishes state diabetes as a range nationally (Colorado 8.4% to West Virginia 18.4%). For Reno we use CDC PLACES instead of interpolating a fake city rate from that range. CDC PLACES (2023, crude) estimates 9.5% of adults in Reno have diagnosed diabetes — 2.5 points below the U.S. 12% figure.

How we’d stand this up in clinic